To include your compound in the COVID-19 Resource Center, submit it here.

Longevity of hemophilia gene therapy in question as BioMarin seeks accelerated approval

As BioMarin reported interim Phase III data Tuesday that sets the company up for regulatory submissions, long-term Phase I/II data cast doubt on the durability of gene therapy valoctocogene roxaparvovec to treat severe hemophilia A. The product is an adeno-associated viral serotype 5 (AAV5) vector delivering the Factor VIII gene.

Among 16 evaluable patients treated with a single

Read the full 573 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE